You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新開源(300109.SZ):擬解除專利權轉讓合同
格隆匯 12-21 16:01

格隆匯 12 月 21日丨新開源(300109.SZ)公佈,公司於2017年6月7日與武漢菲思特生物科技有限公司(“菲思特生物”)與劉丹、孫悦簽署了《專利權轉讓合同》,公司擬用自有資金人民幣4000萬元購買武漢菲思特生物科技有限公司(“菲思特生物”)名下專利號為ZL201310128686.8的“一種用於焦磷酸核酸測序儀的微量加樣方法及其加樣裝置”專利權。經公司考慮未來取得該註冊證主要是生產對應儀器設備,於2017年9月25日公司與菲思特生物與武漢呵爾醫療科技發展有限公司(“呵爾醫療”)簽署《專利權轉讓合同之補充合同》,協議由呵爾醫療接受該專利權及其相應的全部技術資料。

依據《專利權轉讓合同》及《專利權轉讓合同之補充合同》相關條款,約定標的專利的支付包括轉讓費及提成費,其中專利權轉讓費為人民幣2800萬元,提成費為標的專利在收到國家食品藥品監督管理總局核發的正式產品註冊證並進行批量生產後,按每台6萬元向菲思特生物支付提成款,提成款累計最高不超過1200萬元。現因未達到合同約定的目的,經雙方審慎研究決定解除前述專利轉讓相關合同。

公司及子公司無產品使用該項專利,未產生相關銷售收入,該合同的解除不會對公司及子公司的經營和業績產生重大不利影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account